Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-PATCH hydroxychloroquine prevention study for congenital heart block
jRCTs031180312Recruiting
- Sponsor
- Grant-in-Aid for Scientific Research
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxychloroquine in Congenital Atrioventricular Block (CAVB) and neonatal lupus erythematosus (NLE), sponsored by Grant-in-Aid for Scientific Research. Primary endpoint: Congenital heart block (type II or III) during fetal period or at birth. Started Oct 2017; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
Congenital Atrioventricular Block (CAVB)neonatal lupus erythematosus (NLE)
Beyond the preview
Go deeper on jRCTs031180312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180312.